ALK and lung cancer: Data pertaining to CNS penetrance of these agents are now emerging from a number of clinical trials in adults with ALK+ non‐small cell lung cancer (NSCLC) where 7.5% of patients will have brain metastasis at the time of presentation and 25% to 30% will develop brain metastasis during the course of their illness.11, 12